According to a research, the Moderna COVID-19 vaccine is 87% successful in avoiding infection, 95% effective in preventing severe illness, and 98% effective in preventing mortality. The study, which was published in The Lancet Regional Health – Americas journal, looked at the Moderna COVID-19 mRNA vaccine’s five-month efficacy as part of an observational study.
Funded by Moderna, the study included 352,878 recipients of two doses of the vaccine matched to 352,878 unvaccinated individuals by age, sex, race, and ethnicity.
“This research provides reassuring evidence of the high effectiveness of the Moderna COVID-19 vaccine in preventing infection, hospitalisation, and death from COVID-19,” said Katia Bruxvoort, an adjunct investigator with Kaiser Permanente, an integrated health care organisation in Southern California, US.
“One of the important aspects of this study was that it included more than 700,000 adults who were racially and ethnically diverse and had a broad range of underlying conditions including chronic diseases, immunocompromising conditions, and autoimmune conditions,” Bruxvoort said.
In the study, vaccinated individuals received two doses of Moderna COVID-19 vaccine from December 18, 2020, to March 31, 2021.
Both groups were followed up on until June 30, 2021.
COVID-19 infections were found in 289 vaccinated individuals and 1,144 unvaccinated patients during follow-up.
The vaccination had an 87 percent efficiency against COVID-19 infection, according to the researchers.
According to the researchers, 13 vaccinated and 182 unvaccinated people were hospitalised with Covid, and 1 vaccinated and 25 unvaccinated patients died in the hospital.
“This study adds evidence of real-world Moderna COVID-19 vaccine effectiveness, particularly among the general population,” said Hung Fu Tseng, a researcher with the Kaiser Permanente, and the senior author of the study.
